Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.75 USD
Change Today 0.00 / 0.00%
Volume 100.0
BMRA On Other Exchanges
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

biomerica inc (BMRA) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/4/15 - $1.44
52 Week Low
04/22/15 - $0.70
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for BIOMERICA INC (BMRA)

Related News

No related news articles were found.

biomerica inc (BMRA) Related Businessweek News

No Related Businessweek News Found

biomerica inc (BMRA) Details

Biomerica, Inc. develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions worldwide. The company’s diagnostic test kits are used to analyze blood, urine, or fecal samples from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific hormones, antibodies, antigens, or other substances, which may exist in the human body in extremely small concentrations. Its diagnostic products primarily include diabetes, gastrointestinal, food intolerances, and esoteric tests. The company provides its products primarily to distributors, hospital and clinical laboratories, medical research institutions, medical schools, pharmaceutical companies, chain drugstores, wholesalers, and physicians' offices. Biomerica, Inc. was founded in 1971 and is headquartered in Irvine, California.

34 Employees
Last Reported Date: 08/29/14
Founded in 1971

biomerica inc (BMRA) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $141.6K
Chief Financial Officer, Treasurer, Secretary...
Total Annual Compensation: $105.4K
President of Diagnostics Division
Total Annual Compensation: $141.6K
Compensation as of Fiscal Year 2014.

biomerica inc (BMRA) Key Developments

Biomerica Inc. - Special Call

To discuss its product and recent developments in the Irritable Bowel Syndrome (IBS) market

Biomerica, Inc. Names Douglas A. Drossman as Chair of the Scientific Advisory Board; Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2015

Biomerica Inc. announced the formation of a Scientific Advisory Board. This advisory board will assist and guide the company with the FDA regulatory process for its new gastroenterology product, which is now patent pending. The new Scientific Advisory Board is being chaired by Douglas A. Drossman, M.D. and also includes three other key opinion leaders in the field of gastroenterology and Irritable Bowel Syndrome. The company reported earnings results for the third quarter and nine months ended February 28, 2015. For the quarter, the company reported sales of $1,299,400 compared to $1,492,719 for the same period last year. Net loss was $117,193 compared to a net income of $26,544 during the same period in fiscal 2014. For the nine months ended February 28, 2015, the company reported a net loss of $574,483 compared to net loss of $384,532 for the same period in the previous fiscal year. Net sales were $3,467,450 compared to $3,441,299 for the same period in the previous year.

Biomerica, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended November 30, 2014

Biomerica Inc. reported earnings results for the second quarter and six months ended November 30, 2014. The company reported net sales of $1,133,600 for the three months ended November 30, 2014, compared to $934,841 for the same period in the previous year, an increase of 21.3%. Net loss for the three months ended November 30, 2014 was $238,028, or $0.03 per share, versus a net loss of $243,357, or $0.03 per share, in the previous fiscal year during the same quarter. Net sales were $2,168,050 for the first six months of fiscal 2015 compared to $1,948,580 for the first six months in fiscal 2014, an increase of 11.3%. The net loss for the six months ended November 30, 2014 was $457,296, or $0.06 per share, compared to net loss of $411,072, or $0.06 per share, in the same period the previous fiscal year.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMRA:US $0.75 USD 0.00

BMRA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
IDEXX Laboratories Inc $71.34 USD +4.88
Neogen Corp $56.92 USD -0.77
OraSure Technologies Inc $5.06 USD 0.00
Trinity Biotech PLC $17.24 USD +0.74
View Industry Companies

Industry Analysis


Industry Average

Valuation BMRA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.1x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMERICA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at